Dr. Kapil Bharti is a Senior Investigator at the National Eye Institute (NEI), NIH. His lab is running the first U.S. phase I/IIa trial to test autologous-iPSC-derived-RPE-patch in AMD patients. Currently, he is co-developing a dual RPE/photoreceptor cell therapy with Opsis Therapeutics. He has won several awards including NIH Director’s award and NEI Director’s Dr. Karl Kupfer Visionary award his revolutionary work on developing ocular cell-therapies.